Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Solitary Fibrous Tumors 1Sarcoma 1Respiratory Syncytial Virus Infections 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1

Interventions

Cyclophosphamide 28fludarabine 19Rituximab 17obinutuzumab 12venetoclax 10Lenalidomide 9Bendamustine Hydrochloride 9Prednisone 7zanubrutinib 6Doxorubicin 6Blood Specimen Collection 6pembrolizumab 5ibrutinib 5fludarabine phosphate 5Biopsy 5glofitamab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4Exercise 4loncastuximab tesirine 3gamma-Globulins 3axicabtagene ciloleucel 3acalabrutinib 3Temozolomide 3Surveys and Questionnaires 3Palliative Care 3Mycophenolic Acid 3Methotrexate 3Mesna 3Magnetic Resonance Spectroscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma × Suspensions × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡